TransMedics Group, Inc. (TMDX) Average EV/EBIT Ratio
The current ev/ebit ratio for TransMedics Group, Inc. (TMDX) is 34.45x as of Saturday, June 20, 2026, shown against its trailing averages.
Average EV/EBIT Ratio Chart
TMDX EV/EBIT Ratio Averages
EV/EBIT RATIO CURRENT
34.45x
EV/EBIT RATIO TTM
56.95x
EV/EBIT RATIO 3Y
68.54x
EV/EBIT RATIO 5Y
68.54x
EV/EBIT RATIO 10Y
68.54x
EV/EBIT RATIO 15Y
68.54x
EV/EBIT RATIO 20Y
68.54x
About TransMedics Group, Inc.
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Waleed H. Hassanein